LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2067 participants.
Also called NCT01763866
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,067 participants
- Sponsor
- Registry
-
NCT01763866 -
2012-001363-70
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong SAR China, Hungary, Italy, Mexico, Netherlands, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01763866. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-15 (actual); primary completion 2013-11-12 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
- Acronym
- LAPLACE-2
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebo to Evolocumab
- Intervention (Drug)
- Placebo to Ezetimibe
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Simvastatin
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01763866- Content hash
5bb9f8255c409eb20235d1d4ddc780330f8d88ace1ac0f6eb09365da1625a85d